Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H30FN3 |
| Molecular Weight | 367.5028 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCN(CC1)C2=CC(C3=CC=C(F)C=C3)=C4CCCCCCC4=N2
InChI
InChIKey=XVGOZDAJGBALKS-UHFFFAOYSA-N
InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
| Molecular Formula | C23H30FN3 |
| Molecular Weight | 367.5028 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.1 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.26 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.33 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.131 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.3 ng/mL |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.417 ng/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.946 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.679 ng/mL |
12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.538 ng/mL |
2 mg 2 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
0.317 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
0.88 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.195 ng/mL |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.51 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.38 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.46 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.21 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.1457 ng/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.4399 ng/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.4153 ng/mL |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.1293 ng/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.338 ng/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
62.9 pg/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
136.9 pg/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.39 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.23 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.52 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.84 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.91 ng × h/mL |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.6 ng × h/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.13 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.71 ng × h/mL |
12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.06 ng × h/mL |
2 mg 2 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.14 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4.6 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15.5 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
22.3 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
52.2 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.8984 ng × h/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.6219 ng × h/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.6851 ng × h/mL |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.4432 ng × h/mL |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.766 ng × h/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
355.9 pg × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
833.9 pg × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.26 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.4 h |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.1 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
19 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15.5 h |
12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
63.3 h |
2 mg 2 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
12.5 h |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4.5 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7.7 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.7 h |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14.1 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.6 h |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.8 h |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7 h |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.6 h |
5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8 h |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BLONANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.12% |
BLONANSERIN serum | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
80 mg 1 times / day multiple, transdermal Highest studied dose Dose: 80 mg, 1 times / day Route: transdermal Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
8 mg 1 times / day multiple, oral Studied dose Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. | 2013-03 |
|
| Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin. | 2010-12 |
|
| Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. | 2010-10-01 |
|
| Case of delirium complicated with pneumonia that improved with blonanserin administration. | 2010-10 |
|
| Effect of dose timing in relation to food intake on systemic exposure to blonanserin. | 2010-09 |
|
| Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. | 2010-08 |
|
| Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. | 2010-07 |
|
| The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. | 2010-06-04 |
|
| Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. | 2010-04-24 |
|
| Blonanserin: a review of its use in the management of schizophrenia. | 2010-01 |
|
| Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. | 2010 |
|
| Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation. | 2010 |
|
| Efficacy of blonanserin in combination therapy for treatment-resistant depression. | 2009-08 |
|
| The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. | 2009 |
|
| [Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia]. | 2008-12 |
|
| Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. | 2005-02-15 |
|
| Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. | 2004-11-26 |
|
| Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. | 2003-02-10 |
|
| Gateways to clinical trials. | 2002-11 |
|
| Crystal structure of an antipsychotic agent, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (blonanserin). | 2002-11 |
|
| The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics. | 2002-03 |
|
| Blonanserin. AD 5423. | 2002 |
|
| Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. | 1993-01 |
Sample Use Guides
Initial dose is 8 mg/day divided in 2 doses; maintenance dose is 8–16 mg/day divided in 2 doses; maximum dose is 24 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:19:40 GMT 2025
by
admin
on
Wed Apr 02 09:19:40 GMT 2025
|
| Record UNII |
AQ316B4F8C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m2590
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
125564
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
SUB05864MIG
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
388
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
DB09223
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL178803
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
100000086325
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
Blonanserin
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
7670
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
C079310
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
DTXSID7048790
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
132810-10-7
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
C95920
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
AQ316B4F8C
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY | |||
|
7563
Created by
admin on Wed Apr 02 09:19:40 GMT 2025 , Edited by admin on Wed Apr 02 09:19:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
